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To determine whether treatment with the anti-TNF-alpha blocker adalimumab yields persistent improvement of endothelial
function and prevents from morphological progression of subclinical atherosclerosis in patients with rheumatoid arthritis (RA)
refractory to conventional therapy, a series of 34 consecutive RA patients, attending hospital outpatient clinics and who were
switched from disease modifying antirheumatic drug therapy to anti-TNF-alpha-adalimumab treatment because of severe disease,
were assessed by ultrasonography techniques before the onset of adalimumab therapy (at day 0) and then at day 14 and at month
12. Values of flow-mediated endothelium-dependent vasodilatation at day 14 and at month 12 were significantly higher (mean ±
standard deviation (SD): 6.1± 3.9%; median: 5.7% at day 14, and mean ± SD: 7.4± 2.8%; median: 6.9% at month 12) than those
obtained at day 0 (mean: 4.5 ± 4.0%; median: 3.6%; P = 0.03 and P < 0.001, resp.). Endothelium-independent vasodilatation
results did not significantly change compared with those obtained at day 0. No significant differences were observed when carotid
artery intima-media wall thickness values obtained at month 12 (mean± SD: 0.69±0.21 mm) were compared with those found at
day 0 (0.65± 0.16 mm) (P = 0.3). In conclusion, anti-TNF-alpha-adalimumab therapy has beneficial effects on the development
of the subclinical atherosclerosis disease in RA.
1. Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory disease
associated with accelerated atherosclerosis and increased
incidence of cardiovascular (CV) events [1]. Besides a genetic
component [2] and classic (traditional) CV risk factors [3],
chronic inflammation plays a pivotal role in the develop-
ment of atherogenesis in patients with RA [4]. Different
validated techniques are currently available to determine
subclinical atherosclerosis in patients with rheumatic dis-
eases. Macrovascular endothelial dysfunction, an early stage
in atherosclerosis, can be detected by brachial ultrasonogra-
phy as the result of impaired flow-mediated endothelium-
dependent vasodilatation (FMD). Carotid ultrasound studies
are also useful to disclose the presence of subclinical
atherosclerosis [5]. By this technique, morphological changes
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such as abnormally increased carotid artery intima-media
wall thickness (IMT) and carotid plaques can be observed
[5].
A number of studies have shown short-term improve-
ment of endothelial function in RA refractory to disease
modifying antirheumatic drugs (DMARDs) following anti-
TNF-alpha therapy [6, 7]. However, carotid ultrasound stud-
ies in patients with RA undergoing anti-TNF-alpha therapy
have yielded contradictory results in terms of reduction
or progression of carotid IMT [8–10]. Nevertheless, from
a clinical point of view, anti-TNF-alpha therapy has been
associated with a decrease in the incidence of CV events
in patients with RA. In this regard, results from the British
Society for Rheumatology Biologics Register showed that
the risk of myocardial infarction was markedly reduced in
RA patients who responded to anti-TNF-alpha therapy by 6
months compared with nonresponders [11]. Also, in a study
that included 10156 RA patients enrolled in the Consortium
of Rheumatology Researchers of North America, individuals
using a TNF-alpha antagonist experienced a reduced risk
of the primary composite CV endpoint compared with
users of nonbiological DMARDs [12]. In keeping with
these observations, data from a recent systematic review
confirmed that anti-TNF-alpha therapy was associated with
a reduced risk for all CV events, myocardial infarction, and
cerebrovascular accidents [13]. Meta-analysis of randomized
controlled trials also yielded a point estimate indicating a
lower risk of CV events in patients undergoing anti-TNF-
alpha therapy [13].
Taking these observations together, in an attempt to
further investigate the potential beneficial effect of TNF-
alpha antagonist therapy on subclinical atherosclerosis in RA,
we sought to determine whether adalimumab therapy might
yield persistent improvement of endothelial function and
no morphological progression of subclinical atherosclerosis
measured by the determination of carotid artery IMT in RA
patients with severe disease, refractory to DMARDs, who
were prospectively followed over 1 year period.
2. Materials and Methods
2.1. Patients. A series of consecutive RA patients that fulfilled
the 1987 American College classification criteria for RA
[14], attending hospital outpatient clinics from Hospital
Xeral-Calde (Lugo, NW Spain), who were switched from
standard DMARD therapy to anti-TNF-alpha-adalimumab
treatment between April 2008 and May 2009 because of
severe and active disease (DAS28 greater than 5.1) [15],
were assessed before the onset of adalimumab therapy and
then prospectively until 1 year after the commencement of
treatment with this therapy.
For the purpose of this study, RA patients seen during
the period of recruitment with diabetes mellitus, current
smokers, history of coronary heart disease, heart failure,
stroke, peripheral arteriopathy, estimated pulmonary artery
systolic pressure greater than 35 mmHg, mitral, aortic,
tricuspid, pulmonary valve involvement (regurgitation or
stenosis), pericardial effusion in an echocardiography study
performed at the time of recruitment, or body mass index
less than 20 or greater than 35 Kg/m2 were excluded.
Based on the inclusion and exclusion criteria, we
recruited 34 RA white patients (30 women, 28 (82.4%) of
them rheumatoid factor positive). The median age at the
time of disease diagnosis was 50.1 (interquartile range (IQ)
41.3–55.9) years. The delay to the diagnosis of RA from the
onset of symptoms was 0.5 (IQ range 0.3–1.6) years. The
age at the onset of adalimumab therapy was 54.9 (IQ range
47.5–63.0) years. At the commencement of adalimumab,
26 patients were on methotrexate (MTX) therapy (median
15 mg/week) and 14 on leflunomide (20 mg/day), some
of them receiving combination therapy with these two
DMARDs. Six of the 34 patients were also receiving hydrox-
ychloroquine (median 200 mg/day). Twenty-four patients
were on prednisone (median 5 mg/day). Five received non-
steroidal anti-inflammatory drugs. Nine patients had a
history of hypertension. However, in each case appropriate
control of blood pressure was achieved following treat-
ment with antihypertensive drugs. Seven patients received
statins because of hypercholesterolemia. Another 7 were ex-
smokers.
None had ever used nitrates or were on treatment with
estrogens.
Adalimumab therapy (40 mg) was subcutaneously ad-
ministered every 2 weeks over the period of study. Concomi-
tant medication was not changed during the period of study.
The Galician ethical Committee approved this study.
Also, patients signed and informed consent to participate in
this study.
2.2. Study Protocol. Patients received adalimumab therapy
40 mg every other week by subcutaneous injection from day
0 (onset of study) to month 12 (end of the study) 1 year after
the initiation of adalimumab therapy.
In each patient, a DAS 28 (0–10) (determined in each
patient by the same rheumatologist throughout the study)
using erythrocyte sedimentation rate (ESR) as the laboratory
datum was assessed at day 0 (two hours before the first
administration of adalimumab), at day 14 (two hours before
the second administration of adalimumab), and at month
12 (two hours prior to adalimumab administration). Systolic
and diastolic blood pressure, C-reactive protein (CRP-
immunoturbidity method), ESR (Westergren), and serum
creatinine were also determined at day 0 (two hours before
the first administration of adalimumab), at day 14 (two
hours before the second administration of adalimumab), and
at month 12 (two hours before adalimumab administration).
Furthermore, total cholesterol, triglycerides, LDL choles-
terol, HDL cholesterol (fasting overnight determinations),
and total cholesterol/HDL ratio (atherogenic index) were
assessed at day 0, and at month 12.
Endothelial function was assessed before the first admin-
istration of adalimumab (two hours before) at day 0 at
day 14 (two hours before the second administration of
adalimumab), and at month 12 (at the end of the study, two
hours before adalimumab administration).
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Figure 1: Changes in DAS28 (a) and C-reactive protein (b) from day 0 onwards, obtained via locally weighted regression. Central estimate
and lower and upper limits of 95% confidence bands.
Carotid artery IMT was measured before the first admin-
istration of adalimumab (two hours before) and at month 12
(at the end of the study).
Flow-mediated endothelium-dependent vasodilatation
(postischemia) FMD and independent vasodilatation (post-
nitroglycerin) NTG were measured by brachial ultrasonog-
raphy. Brachial artery diameter and flow were determined
as previously described [16, 17]. B-mode scan of the right
brachial artery, in a longitudinal Section 2 to 12 cm proximal
to the antecubital fossa, was performed in supine subjects
using a Philips IE33 (Philips Healthcare, DA Best, The
Netherlands) with a 11 MHz linear transducer. The anterior
and posterior media-intima interfaces were used to define
the baseline artery diameter, calculated as the average of
measurements made during four cardiac cycles at end
diastole. The forearm blood pressure cuff was inflated on
the ipsilateral wrist to 50 mmHg above resting systolic blood
pressure for 5 minutes and then released. FMD (an increase
in brachial artery diameter) was measured from 30 to 60
seconds after cuff release. To assess NTG endothelium-
independent vasodilatation, we used 400 μg of sublingual
nitroglycerin, which acts directly on vessel smooth muscle
to cause vasodilatation. NTG was measured 4 minutes after
nitroglycerin intake. Intraobserver variability showed the
following coefficients of variation: FMD 1.3% and NTG
1.9%.
Assessment of carotid artery IMT was performed as
previously described in recent studies from our group [18,
19]. Briefly, carotid IMT was measured in the right common
carotid. The study was performed using high-resolution B-
mode ultrasound (Philips IE33; Philips Healthcare, DA Best,
The Netherlands) with an 11 MHz linear transducer. For the
purpose of the present study, QLAB’s IMT-quantification
software measurement plug in (Philips Healthcare, DA Best,
The Netherlands) was used to increase the consistency and
reliability of IMT measurements, reduce the effort required
to successfully carry out IMT measurements, and minimize
the time needed to complete an IMT study. The repro-
ducibility of the IMT measurements was evaluated in 10
patients within 1 week of the first ultrasound examination.
The correlation coefficient for carotid IMT was 0.985.
In all cases a cardiologist (CG-J) analyzed ultrasound
data offline and he was blind to the clinical information and
study date.
2.3. Statistical Analysis. Data were expressed as mean ±
SD, median, and IQR. Measurements of FMD and NTG
represented the maximal increase in brachial diastolic artery
diameter and were expressed as percentage of change (%)
from baseline. Equality of values at day 0 versus day 14 and
at day 0 versus month 12 was tested using the Wilcoxon
matched-pairs signed-rank test. All tests were two tailed.
Statistical significance was accepted at P < 0.05.
Figures on the evolution from day 0 on (onwards) were
obtained via locally weighted regression; its results were
displayed with three curves representing the central estimate
and lower and upper limits for confidence bands.
3. Results
The use of anti-TNF-alpha-monoclonal antibody-adali-
mumab yielded clinical improvement in this series of
RA with severe disease refractory-to-conventional DMARD
therapy (Figure 1). DAS28 values at month 12 were signif-
icantly reduced (mean ± SD: 3.3 ± 1.5; median: 3.3) when
compared to those observed before the onset of adalimumab
therapy at day 0 (mean ± SD: 5.9 ± 0.7; median: 5.9;
P < 0.001) (Table 1). Moreover, a significant reduction
in the serum levels of CRP was achieved following the
administration of adalimumab at day 14 (median: 4.9 mg/L)
compared to baseline levels observed at day 0 (median:
9.1 mg/L; P = 0.008) (Table 1).
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Table 2: Changes in the lipid profile and blood pressure levels in 34 patients undergoing anti-TNF-alpha-adalimumab therapy due RA
refractory to conventional DMARDs.
Variable
Day 0 Month 12 Day 0 versus month 12
Mean ±SD Mean ±SD P
Total cholesterol (mg/dL) 206.1 ±33.5 208.2 ±40.7 0.94
LDL-cholesterol (mg/dL) 125.4 ±4.8 124.8 ±38.8 0.90
HDL-cholesterol (mg/dL) 60.4 ±15.8 61.8 ±14.7 0.96
Atherogenic index 3.61 ±1.03 3.51 ±0.98 0.73
Triglycerides (mg/dL) 101.6 ±5.5 108.7 ±4.1 0.31
Systolic blood pressure (mmHg) 136.0 ±17.8 126.9 ±18.2 0.10
Diastolic blood pressure (mmHg) 81.6 ±9.6 79.2 ±11.6 0.36



























   
   
   
   
   
   
   
   



































   
   
   
   
   
   
   
   








Figure 2: Changes in flow-mediated endothelium-dependent (FMD%) (a) and endothelium-independent (NTG%) vasodilatation (b) from
day 0 onwards, obtained via locally weighted regression. Curves are central estimate and lower and upper limits of 95% confidence bands.
However, no statistically significant differences were
found when total cholesterol, HDL-cholesterol and LDL-
cholesterol, levels observed at month 12 were compared
with those found at day 0. This was also the case for the
atherogenic index (Table 2).
As previously described in RA patients with long-
standing disease [20], this series of RA patients also had
endothelial dysfunction prior to the onset of adalimumab
therapy as the mean and median FMD percentage values
were lower than 7% [21]. In addition, the present study
confirmed a short-term rapid and significant improvement
of endothelial function following the first administration of
adalimumab [7]. In this regard, at day 14, values of FMD
percentage were significantly higher (mean ± SD: 6.1 ±
3.9%; median: 5.7%) than those observed at day 0 (mean
± SD: 4.5 ± 4.0%; median: 3.6%; P = 0.03) (Table 1).
Moreover, persistent improvement of endothelial function
was observed at the end of the study (Figure 2). With respect
to this, values of FMD percentage at month 12 (mean ± SD:
7.4 ± 2.8%; median: 6.9%) were significantly higher than
those observed at day 0 (P < 0.001) (Table 1). However,
no statistically significant differences were achieved when
NTG percentage values observed at day 0 were compared
with those obtained at day 14 or at month 12 (Table 1 and
Figure 2).
No statistically significant changes were found when
carotid artery IMT results obtained at month 12 (mean± SD:
0.69 ± 0.21 mm; median: 0.68) were compared with those
obtained at day 0 (mean± SD: 0.65±0.16 mm; median: 0.64;
P = 0.30) (Table 1). Therefore, no significant morphological
progression of subclinical atherosclerosis was observed in
this series of adalimumab-treated RA patients.
4. Discussion
The present study shows persistent improvement of endothe-
lial function following the TNF-alpha antagonist adali-
mumab in a cohort of patients with RA refractory to conven-
tional DMARD therapy. Also, unlike our previous observa-
tions on patients with severe disease undergoing treatment
with the chimeric anti-TNF-alpha monoclonal antibody-
infliximab [8], no progression of subclinical atherosclerosis
was observed after 1 year of adalimumab therapy.
A recent study on 8 early RA patients (disease duration
≤ 1 year), treated with adalimumab during 6 months,
showed significant improvement of endothelial function that
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inversely correlated with CRP levels [22]. Sidiropoulos et al.
also demonstrated an improvement of endothelial function
after 18 months therapy with infliximab or adalimumab
[23]. In keeping with these observations, we observed that
adalimumab therapy yielded improvement of endothelial
function after 12 months of therapy. However, the beneficial
effect on endothelial dysfunction does not seem to be
specific of anti-TNF-alpha drugs as therapy with rituximab,
a monoclonal antibody that selectively targets CD20 positive
B cells, demonstrated in two different studies an early
and sustained favorable effect on endothelial function in
RA patients refractory to TNF-alpha blockers [17, 24]. In
a former study of our group, we demonstrated that in
long-term anti-TNF-α infliximab-treated RA patients, the
intravenous infusion of this monoclonal antibody yielded a
significant rapid but transient improvement of endothelial
dysfunction [25]. In this regard, following infusion of the
drug, a dramatic and rapid increase in the percentage of
FMD was observed. In all patients, percentages of FMD were
greater than those observed 2 days before infusion. However,
of FMD percentage values returned to baseline by 4 weeks
after infusion of the drug. Therefore, we think differences
in the bioavailability of the different TNF-α blockers may
be a possible explanation for the persistent positive effect
of adalimumab on endothelial function in long-term RA
patients when compared with data obtained in long-standing
RA patients following a single infusion of infliximab.
A result derived from the present study is that the
improvement of endothelial function in RA seems to be
independent of the effect of these biologic agents on the
lipid profile. In this regard, although dyslipidemia is also
closely linked to the development of endothelial dysfunction
and atherosclerosis [1], short-term infliximab therapy was
associated with significant increase of both total cholesterol
and HDL cholesterol levels [26], plasma total cholesterol
concentrations, LDL cholesterol concentrations, and also the
atherogenic index increased after 1 year from the start of
this therapy [26]. In accordance with these observations, in
our study we did not observe a significant change in the
atherogenic index when results obtained at month 12 were
compared with baseline results.
Atherosclerosis is increasingly considered to be an
immune system-mediated process of the vascular system
and the inflammatory process taking place in the arterial
wall as part of atherosclerosis disease. The actual evidence
suggests that proinflammatory cytokines and metabolic
abnormalities associated with systemic inflammation may be
implicated in the development of endothelial dysfunction
in RA. The chronic inflammation may lead to endothelial
dysfunction, subsequent atherosclerosis, and cardiovascular
events in RA [1].
Regardless of the biologic agent used (viz., adalimumab,
infliximab, or rituximab), improvement of endothelial dys-
function has been demonstrated in RA patients that exhibit
low levels of inflammation and clinical remission. In this
regard, RA patients with early diagnosed disease treatment
with adalimumab yielded improvement of endothelial func-
tion that was significantly related to clinical remission [22].
In keeping with that, although in our study reduction of
blood pressure following 12-month adalimumab therapy did
not reach statistical significance, it is remarkable to see that
both the mean systolic and diastolic blood pressure were
reduced in adalimumab-treated patients when compared
with baseline results of blood pressure obtained at the onset
of this biologic therapy. To the best of our knowledge, this
reduction of blood pressure levels in long-term adalimumab-
treated patients has not previously been reported. Whether
the reduction of blood pressure levels following 12-month
adalimumab therapy is the consequence of the decrease of
the systemic inflammatory burden is a question that still
remains unanswered. However, we feel that it may be a
plausible explanation for these findings.
Carotid IMT is a useful surrogate marker of subclinical
atherosclerosis and a predictor of CV events in patients with
RA [27]. Due to this, as discussed before, another important
result derived from the present study was the lack of
significant increase of the carotid IMT following 12 months
of adalimumab therapy. Previous studies on high resolution
B-mode ultrasound of the common carotid artery disclosed
a strong correlation between the carotid IMT and markers
of systemic inflammation in both controls and patients with
RA [4, 28]. Studies that addressed the effect of the control
of CV risk factors on the progression of atherosclerosis,
as measured by carotid IMT, used the concept of “change
in the progression of IMT” because progression in the
measurements of carotid IMT is expected with time/age [29]
and because a reduction in this progression should be of
great clinical significance. With respect to this, anti-TNF
blocking agents, but not MTX, have been found to reduce
carotid IMT in patients with RA [9, 10, 22]. In line with
these studies, no progression in the carotid IMT was found
in our series of adalimumab-treated patients. However,
despite having a reduction in markers of inflammation, we
could not disclose a decrease in the carotid IMT in our
series. Nevertheless, the absence of carotid IMT progression
enhances the potential usefulness of the TNF-alpha blocker
therapy to decrease the accelerated atherosclerosis observed
in patients with RA.
5. Conclusion
Twelve-month adalimumab therapy reduces mechanisms
implicated in the increased risk of CV death observed in
patients with RA.
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Garcia-Porrua, A. Testa, and J. Llorca, “High-grade C-reactive
protein elevation correlates with accelerated atherogenesis in
patients with rheumatoid arthritis,” Journal of Rheumatology,
vol. 32, no. 7, pp. 1219–1223, 2005.
[29] G. Howard, A. R. Sharrett, G. Heiss et al., “Carotid artery
intimal-medial thickness distribution in general populations
as evaluated by B-mode ultrasound,” Stroke, vol. 24, no. 9, pp.
1297–1304, 1993.
